PATH, ULTA and CAN are among pre market gainers
Jeffs Brands +64%Received Regulatory Approvals in Spain and The Netherlands to Commence Sales.Altimmune +38%pulls back from twice-daily regime of weight-loss drug candidate.Biora Therapeutics +29%clears Biora to begin Phase 1 testing of ulcerative colitis treatment.